Evolve is a new kind of biologics company. We’re built around a next-generation technology for bringing critical therapeutics to the people who need them. People with many rare diseases rely on therapies made from proteins extracted from blood plasma. For the past 80 years, these proteins have been captured through a largely unchanged yet expensive process. Until now. We believe our patented next-generation technology, PlasmaCap EBA®, is the first major advancement in the field since the 1940s. We believe it will help us deliver critical plasma-derived therapeutics at higher levels of purity, efficiency, and quality than conventional methods can. Ultimately, Evolve aims to improve the lives of people within a largely underserved market—building a broad and innovative product portfolio in the process.Something looks off?